A first-of-its kind trial will explore the benefits of vagus nerve stimulation for stroke rehabilitation; plus, can a brain implant restore vision to the blind?
A hyped status epilepticus drug falls flat in phase 3; misconceptions about vaccines and autism influence health care decisions in siblings.
Fingolimod proves effective in pediatric patients with MS while radiologists face a future where technology may replace them.
The FDA denies a NDA for an up-and-coming Parkinson's drug over manufacturing issues while researchers discover significant sex-specific differences in the brains of people with depression.
Will a mini-dystrophin gene be the key to treating muscular dystrophy? Plus, a recent recall of an epilepsy drug and updated practice guidelines.
MS drug makers are coming under fire for rapidly rising drug prices while another lawsuit is filed against Purdue Pharma for deceptive marketing practices for OxyContin.
Eli Lilly reports more positive phase 3 data for its acute migraine drug lasmiditan, while yet another brain-training company comes under fire for making baseless claims.
The NIH-NFL partnership for brain research is walking away from millions of unspent money. Plus, are girls better at masking autism symptoms?
FDA recalls Penumbra revascularization device while Amgen reaches the FDA first with its CGRP migraine drug erenumab.
Senator John McCain has been handed a grim neurological diagnosis. Plus, a new headache treatment is on the market.
State drug agencies face a new and growing threat in gabapentin abuse as the NIH battles through a brain tissue shortage.
Researchers say serotonin levels may be a biomarker of SIDS. Plus, new findings may help develop therapeutics that can better penetrate the blood-brain barrier.
Researchers plan a controversial trial to use stem cells to try and reverse brain death. Plus, protective mutation A673T lends support to the amyloid hypothesis, and the molecule LRP4 may shed light on synaptic imbalances that can lead to epilepsy.
Patients are facing major backlash from insurers refusing to cover the cost of a controversial Duchenne muscular dystrophy drug while the National Academies of Sciences are recommending steps to prevent dementia.
A large genomic study has identified 5 genes related to insomnia, plus hear from the DAWN trial investigators on the impact their data might have on the future of stroke treatment.
In a first, the FDA has requested the removal of an opioid medication from the market. Plus, is snake venom the latest antiplatelet agent?
New research suggests that ketamine may do more harm than good when it comes to preventing delirium, plus is an old, cheap, generic drug about to be repurposed for another neurologic disorder?
What US hospitals can learn from the ransomware attack on the UK health care system, plus the latest hurdle for Sarepta's DMD drugs.
A new treatment for ALS gets a green light from the FDA as the NIH prepares to take a deep dive into chronic fatigue syndrome.
A third of the population has experienced "mini" stroke, but most don't know how to handle it. Plus, catch up on the latest drug price controversy for rare-disease drugs.
Did you miss out on AAN? Catch up on the latest science with Neurology Advisor's live coverage, plus learn about the latest FDA approval.
A report ties over 4000 children with birth defects to a popular epilepsy drug, while the FDA issues a stern warning about the use of codeine and tramadol in children.
The latest studies suggest that silencing the SCA2 gene may help reduce symptoms of ALS and deep brain stimulation may quell tics associated with Tourette's syndrome.
Teva's Huntington's chorea drug names a competitive price as other drug makers pursue phase 3 studies in glioblastoma and depression despite disappointing data.
Pricing criticism strikes Roche's Ocrevus as the nominee for FDA commissioner comes under fire for potential conflicts of interest.
The CDC says we should be paying more attention to fall-related concussion prevention in the elderly while one of the NFL's own heads to Harvard for a neurosurgery residency.
Marathon sells off its controversial DMD drug as the FDA stands to double its fees for the drug approval process under the new Trump budget.
The Obamacare replacement is here, and opposition is growing among medical groups. Plus, alternative medicine is having its moment at some major hospitals, while telemedicine proves to be a bust for health care costs.
While Genentech rolls the dice on a second phase 3 trial for its anti-amyloid agent, a new biotech startup is tapping CRISPR technology to restore dystrophin production in Duchenne muscular dystrophy.
Follow timely coverage of the International Stroke Conference right here on Neurology Advisor.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies